Robert L. Grossman

Practice Details

• Payment Information
  Accepted Credit Cards

  American Express
• Firm Information
  Position

  Shareholder; Co-Chair, Israel Practice

  Firm Name

  Greenberg Traurig, LLP
• Representative Cases & Transactions
  Cases

  Experience: Capital Markets: Represented Frost Group in an investment in Protalix
  in the transaction by which Protalix became a public company.
  Represented UBS in a public offering of Protalix Ltd.
  Represented Prolor Biotech, Inc. in a public offering.
  Represented various underwriters in public offerings, including public offerings of Israeli companies.
  Representing Galmed Pharmaceuticals, Ltd. in its initial public offering.
  Represented Integrity Applications, Inc. in becoming a publicly reporting company.
  Represented Intec Pharma Ltd. in its initial public offering
  in a secondary public offering.
  Represented Glasses Off, Inc. in a reverse merger
  private placement pursuant to which the Company went public.
  Represented an Israeli pharmaceutical company in listing Level II ADRs.
  Represented an Israeli company public in Singapore in listing Level I ADRs.
  Represented Castle Br
  s, Inc. in an ATM offering.
  Represented an Israeli medical device company in a $150 million private placement.
  Represented Intec Pharma Ltd. in a $10 million private placement.
  Represented Castle Br
  s, Inc., developer
  international marketer of premium
  super premium alcoholic beverage br
  s, in a private placement (PIPE) of convertible preferred stock
  warrants to various investors, including the conversion of various tranches of the issuer's existing debt into preferred stock.
  Represented Enlivex Therapeutics Ltd. in various private placements
  public offerings.
  Represented Integrity Applications in various private placements.
  Represented Autobrain Inc. in private placements.
  Represented numerous U.S., Israeli
  other private life science
  technology companies in various private placements.
  Represented Orbimed Israel in PIPE investment in Red Hill BioPharma Ltd.
  Represented Orbimed Israel in registered direct investment in BiolineRx, Ltd.
  Represented Orbimed Israel in its investment in FUSMobile, Inc.
  Represented various public companies as outside securities counsel.
  
  Mergers
  Acquisitions: Represented IVAX Corporation in its merger with TEVA Pharmaceutical Industries Ltd.
  Represented a leading pharmaceutical company in a $2.3 billion acquisition.
  Represented OPKO Health, Inc. in the $1.4 billion acquisition of Bioreference Labs.
  Represented Prolor Biotech, Inc. in its acquisition by OPKO Health, Inc.
  Represented a mobile virtual network operator (MVNO), a subsidiary of a public company, with its approximately $120 million acquisition of substantially all of the assets
  assumption of certain of the liabilities of another MVNO that provides prepaid SIM cards to its customers.
  Represented the representative of the shareholders of Beeologics in its sale of all the stock of Beeologics Holdings Limited, a Cyprus entity,
  Beeologics, Inc., a BVI entity, to Monsanto Company.
  Represented a Japanese public technology company in the acquisition of an Israeli technology company for over $200 million.
  Represented Scivac Ltd. in its merger with Levon Resources Ltd.
  Representing Scivac Ltd. in its acquisition of VBI Vaccines Inc 8.
  Represented OPKO Health, Inc. (NYSE: OPK) in connection with its acquisition of Claros Diagnostics, Inc. a private company engaged in the development
  marketing of medical diagnostic devices.
  Represented OPKO Health, Inc. in an investment in RXI Pharmaceuticals
  the transfer of certain technology
  sale of certain assets to RXI.
  Represented Ladenburg Thalmann Financial Services, Inc. in its acquisition of Securities America
  its subsidiaries.
  Represented a private equity firm in its sale of 87 Wendy's franchises.
  Represented Devcon International Corp. in its acquisition of Adelphia electronic security services assets.
  Represented Israeli pharmaceutical company Immune Pharmaceuticals Ltd. in a reverse triangular merger with EpiCept Corporation, a U.S.
  Swedish publicly traded biopharmaceutical company, whereby Immune became a wholly owned subsidiary of,
  Immune's shareholders obtained a controlling interest in, EpiCept, which is now known as Immune Pharmaceuticals Inc.
  Represented various life science companies in license
  distribution agreements
  corporate transactions
  matters.
  Represented Orthodontix, Inc.
  The Frost Group in a reverse merger with
  investment into Protalix Ltd. pursuant to which Protalix became a publicly reporting company.
  
• Additional Links
  http://www.gtlaw.com/People/Robert-L-Grossman